CML: mechanisms of disease initiation and progression - PubMed (original) (raw)
Review
CML: mechanisms of disease initiation and progression
M Wetzler et al. Leuk Lymphoma. 1993.
Abstract
Chronic myelogenous leukemia (CML) is a hematological stem cell disorder characterized by excessive proliferation of the myeloid lineage. It has a progressive course typified by the transition from the chronic phase to the accelerated phase and on to blast crisis. The hallmark of CML is the translocation between chromosomes 9 and 22 that results in the chimeric BCR-ABL gene encoding p210BCR-ABL. The oncogenic potential of this protein has been validated, and it is believed that it contributes in a critical way to the initiation of CML. However, the secondary genetic forces responsible for the transition from the chronic state to the fully blastic stage are not clear. Evidence for chromosomal instability includes the clonal evolution which characterizes advanced CML. In regard to specific genetic aberrations, sporadic reports have shown alterations in H-RAS, c-MYC, retinoblastoma, and P53 genes, as well as production of p190BCR-ABL during the progression of CML. In addition, we have recently found evidence for excessive interleukin-1 beta production, acting in an autocrine and/or paracrine manner, in the more advanced stages of the disease. Taken together, current data suggest that multiple molecular pathways lead to disease progression, and that distinct subsets of genetic alterations exist in blast crisis patients.
Similar articles
- The molecular biology of chronic myeloid leukaemia.
Melo JV. Melo JV. Leukemia. 1996 May;10(5):751-6. Leukemia. 1996. PMID: 8656667 Review. - Increase of bcr-abl chimeric mRNA expression in tumor cells of patients with chronic myeloid leukemia precedes disease progression.
Gaiger A, Henn T, Hörth E, Geissler K, Mitterbauer G, Maier-Dobersberger T, Greinix H, Mannhalter C, Haas OA, Lechner K, Lion T. Gaiger A, et al. Blood. 1995 Sep 15;86(6):2371-8. Blood. 1995. PMID: 7662984 - No correlation between locations of bcr breakpoints and clinical states in Ph1-positive CML patients.
Ogawa H, Sugiyama H, Soma T, Masaoka T, Kishimoto S. Ogawa H, et al. Leukemia. 1989 Jul;3(7):492-6. Leukemia. 1989. PMID: 2733454 - Molecular pathogenesis of chronic myeloid leukemia: implications for new therapeutic strategies.
Warmuth M, Danhauser-Riedl S, Hallek M. Warmuth M, et al. Ann Hematol. 1999 Feb;78(2):49-64. doi: 10.1007/s002770050473. Ann Hematol. 1999. PMID: 10089019 Review. - Acquired loss of p53 induces blastic transformation in p210(bcr/abl)-expressing hematopoietic cells: a transgenic study for blast crisis of human CML.
Honda H, Ushijima T, Wakazono K, Oda H, Tanaka Y, Aizawa Si, Ishikawa T, Yazaki Y, Hirai H. Honda H, et al. Blood. 2000 Feb 15;95(4):1144-50. Blood. 2000. PMID: 10666183
Cited by
- Expression of BCR/ABL and BCL-2 in myeloid progenitors leads to myeloid leukemias.
Jaiswal S, Traver D, Miyamoto T, Akashi K, Lagasse E, Weissman IL. Jaiswal S, et al. Proc Natl Acad Sci U S A. 2003 Aug 19;100(17):10002-7. doi: 10.1073/pnas.1633833100. Epub 2003 Jul 30. Proc Natl Acad Sci U S A. 2003. PMID: 12890867 Free PMC article. - Presence of P210bcrabl is associated with decreased expression of a beta chemokine C10 gene in a P210bcrabl-positive myeloid leukemia cell line.
Lane CM, Guo XY, Macaluso LH, Yung KC, Deisseroth AB. Lane CM, et al. Mol Med. 1999 Jan;5(1):55-61. Mol Med. 1999. PMID: 10072448 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous